Kronos Bio

📍 San Mateo, United States🗓 Founded 2017👥 98 employees💰 Last funded Jul 2019
Biotechnology Research🌐 kronosbio.com
Website LinkedIn
Kronos Bio is a clinical-stage biopharmaceutical company developing therapeutics that target the dysregulated transcription that causes cancer and other serious diseases. Our pipeline includes two investigational oral SYK inhibitors, entospletinib and lanraplenib, which are being developed to treat acute myeloid leukemia (AML). Together the compounds have the potential to target mutations present in more than two-thirds of patients with AML. We are also advancing an oral CDK9 inhibitor, KB-0742, to treat patients with solid tumors addicted to oncogenic transcription factor activity. KB-0742 is the first investigational medicine from our internal discovery platform to enter the clinic. Beyond these three investigational compounds, we are progressing additional discovery programs, including one focused on the MYC TRN and another focused on the AR TRN. For additional information about our community guidelines, visit: https://bit.ly/3FfcDQW.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2017
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in Kronos Bio?
Kronos Bio has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Kronos Bio last raise funding?
The most recent investment in Kronos Bio recorded on gritt.io was in July 2019.
When was Kronos Bio founded?
Kronos Bio was founded in 2017.
What industry is Kronos Bio in?
Kronos Bio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Kronos Bio based?
Kronos Bio is headquartered in San Mateo, United States.